211 related articles for article (PubMed ID: 26994815)
1. Meningococcemia in vaccinated patient under treatment with eculizumab.
Hernando Real S; Vega Castaño S; Pajares García R
Enferm Infecc Microbiol Clin; 2017 Mar; 35(3):200-201. PubMed ID: 26994815
[No Abstract] [Full Text] [Related]
2. [With paroxysmal nocturnal haemoglobinuria and treatment with eculizumab].
Algado JT; Luque R; Nuñez R; Sanchez B
Enferm Infecc Microbiol Clin; 2012 Feb; 30(2):109-10. PubMed ID: 22197277
[No Abstract] [Full Text] [Related]
3. Differential effects of therapeutic complement inhibitors on serum bactericidal activity against non-groupable meningococcal isolates recovered from patients treated with eculizumab.
Granoff DM; Kim H; Topaz N; MacNeil J; Wang X; McNamara LA
Haematologica; 2019 Aug; 104(8):e340-e344. PubMed ID: 30705094
[No Abstract] [Full Text] [Related]
4. Fatal Nongroupable Neisseria meningitidis Disease in Vaccinated Patient Receiving Eculizumab.
Nolfi-Donegan D; Konar M; Vianzon V; MacNeil J; Cooper J; Lurie P; Sedivy J; Wang X; Granoff DM; McNamara L
Emerg Infect Dis; 2018 Aug; 24(8):1561-4. PubMed ID: 30015608
[TBL] [Abstract][Full Text] [Related]
5. Fatal meningococcemia due to Neisseria meningitidis serogroup Y in a vaccinated child receiving eculizumab.
Polat M; Yüksel S; Şahin NÜ
Hum Vaccin Immunother; 2018; 14(11):2802. PubMed ID: 29883245
[No Abstract] [Full Text] [Related]
6. A rare case of septic shock due to Neisseria meningitidis serogroup B infection despite prior vaccination in a young adult with paroxysmal nocturnal haemoglobinuria receiving eculizumab.
Reher D; Fuhrmann V; Kluge S; Nierhaus A
Vaccine; 2018 May; 36(19):2507-2509. PubMed ID: 29631884
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic amoxicillin for the prevention of meningococcal infection in infants with atypical hemolytic uremic syndrome under treatment with eculizumab: a report of two cases.
Tanaka K; Fujita N; Hibino S
CEN Case Rep; 2020 Aug; 9(3):247-251. PubMed ID: 32240525
[TBL] [Abstract][Full Text] [Related]
8. [Meningococcemia and meningitis due to Neisseria meningitidis W135 developed in two cases vaccinated with bivalent (A/C) meningococcal vaccine].
Turhan V; Acar A; Kılıç A; Budak S; Oncül O; Haznedaroğlu T; Görenek L
Mikrobiyol Bul; 2010 Jul; 44(3):473-8. PubMed ID: 21063998
[TBL] [Abstract][Full Text] [Related]
9. Post-eculizumab meningococcaemia in vaccinated patients.
Lebel E; Trahtemberg U; Block C; Zelig O; Elinav H
Clin Microbiol Infect; 2018 Jan; 24(1):89-90. PubMed ID: 28736073
[No Abstract] [Full Text] [Related]
10. Eculizumab impairs Neisseria meningitidis serogroup B killing in whole blood despite 4CMenB vaccination of PNH patients.
Langereis JD; van den Broek B; Franssen S; Joosten I; Blijlevens NMA; de Jonge MI; Langemeijer S
Blood Adv; 2020 Aug; 4(15):3615-3620. PubMed ID: 32766853
[TBL] [Abstract][Full Text] [Related]
11. Antibiotic prophylaxis in vaccinated eculizumab recipients who developed meningococcal disease.
Crew PE; McNamara L; Waldron PE; McCulley L; Christopher Jones S; Bersoff-Matcha SJ
J Infect; 2020 Mar; 80(3):350-371. PubMed ID: 31783062
[No Abstract] [Full Text] [Related]
12. [Chronic meningococcemia due to Neisseria meningitidis serogroup B].
García-Irure JJ; Cabodevilla B; Sanchiz JR; Martín C
Enferm Infecc Microbiol Clin; 1999 Dec; 17(10):536. PubMed ID: 10650657
[No Abstract] [Full Text] [Related]
13. Infections by emerging serogroups of Neisseria meningitidis: A case report.
Pérez-García F; Abad R; Almirall C; Abarca E
Enferm Infecc Microbiol Clin (Engl Ed); 2019 Feb; 37(2):142-143. PubMed ID: 29724617
[No Abstract] [Full Text] [Related]
14. The Brief Case: Meningococcemia Leading to a Diagnosis of Complement Deficiency in a 23-Month-Old.
Brostowski LE; Graf EH
J Clin Microbiol; 2019 Feb; 57(2):. PubMed ID: 30700562
[No Abstract] [Full Text] [Related]
15. Serologic response to meningococcal vaccination in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with the terminal complement inhibitor eculizumab.
Alashkar F; Vance C; Herich-Terhürne D; Preising N; Dührsen U; Röth A
Ann Hematol; 2017 Apr; 96(4):589-596. PubMed ID: 28124080
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of and meningococcal disease prevention strategies for commercially insured persons receiving eculizumab in the United States.
Bozio CH; Isenhour C; McNamara LA
PLoS One; 2020; 15(11):e0241989. PubMed ID: 33180804
[TBL] [Abstract][Full Text] [Related]
17. Successful cholecystectomy in a patient with aplastic anemia-paroxysmal nocturnal hemoglobinuria during eculizumab treatment.
Ando K; Gotoh A; Yoshizawa S; Gotoh M; Iwabuchi T; Ito Y; Ohyashiki K
Ann Hematol; 2012 Dec; 91(12):1987-8. PubMed ID: 22739575
[No Abstract] [Full Text] [Related]
18. Immunogenicity of meningococcus C vaccination in a patient with atypical hemolytic uremic syndrome (aHUS) on eculizumab therapy.
Zlamy M; Hofer J; Elias J; Vogel U; Frosch M; Jungraithmayr T; Zimmerhackl LB; Prelog M
Pediatr Transplant; 2012 Sep; 16(6):E246-50. PubMed ID: 21967634
[TBL] [Abstract][Full Text] [Related]
19. High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine.
McNamara LA; Topaz N; Wang X; Hariri S; Fox L; MacNeil JR
MMWR Morb Mortal Wkly Rep; 2017 Jul; 66(27):734-737. PubMed ID: 28704351
[TBL] [Abstract][Full Text] [Related]
20. Waterhouse-Friderichsen syndrome due to Neisseria meningitidis infection in a young adult with thrombotic microangiopathy and eculizumab treatment: case report and review of management.
Friedl C; Hackl G; Schilcher G; Rosenkranz AR; Eller K; Eller P
Ann Hematol; 2017 May; 96(5):879-880. PubMed ID: 28213751
[No Abstract] [Full Text] [Related]
[Next] [New Search]
